Saturday, 3 October 2026European Markets

ACANTHE DEV. Stock Was Up By 17.38% On Monday

Loading stream...

(vianews) - the market ended the session with acanthe dev. (acan.pa) jumping 17.38% to €0.36 on monday, following the last session's downward trend. cac 40 fell 0.21% to €7,449.44, after two consecutive sessions in a row of gains, on what was a somewhat negative trend trading session today.

acanthe dev.'s last close was €0.31, 38.76% below its 52-week high of €0.50.

about acanthe dev.

as of december 31, 2022, acanthe développement's real estate portfolio represents an area of 9,374 m². during the year, the group sold, for €9.2 million, lots held in a building located on the left bank in paris. all of the group's buildings have been subject to appraisals, mainly carried out by the firm vif expertise on december 31, 2022. the overall appraised value of the property portfolio (investment properties and building occupied by the group) amounts to €117.1 million, an increase, at constant scope, of €1.6 million (+1.4%) compared to 2021. this increase in value confirms the relevant investment policy of the group in the central business district of paris. the appraised value of the assets stands at €117.1 million.

earnings per share

as for profitability, acanthe dev. has a trailing twelve months eps of €-0.08.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -8.6%.

revenue growth

year-on-year quarterly revenue growth grew by 7.7%, now sitting on 3.97m for the twelve trailing months.

more news about acanthe dev. (acan.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com